Worldwide, 387 million people suffer from diabetes (WHO, 2015). Of these, 153 million people are treated with insulin injections, $24B annual revenues. To provide an effective treatment for diabetes, Betalin Therapeutics ('Betalin') is developing the Engineered Micro Pancreas (EMP), a breakthrough technology that within few days following a simple under the skin injection of EMPs, the patient will no longer need to use insulin injections and will restore the body's intrinsic insulin generation capabilities. Since diabetes is a huge market with unmet need (insulin revenues are $24b/year), Betalin has a relatively fast regulatory track, and that there are two family of patents accepted already in Europe and USA, there is a huge investment opportunity. Betalin is seeking for $3M and this will allow activity that will increase company value 10 times the least!